| scholarly article | Q13442814 |
| P2093 | author name string | Daisuke Inoue | |
| Toshio Matsumoto | |||
| Toshihiro Hashimoto | |||
| Masahiro Abe | |||
| Keiji Moriyama | |||
| Masaaki Kosaka | |||
| Shuji Ozaki | |||
| Shinsuke Kido | |||
| Shingo Wakatsuki | |||
| Kenji Hiura | |||
| Javier Wilde | |||
| P433 | issue | 6 | |
| P921 | main subject | macrophage | Q184204 |
| multiple myeloma | Q467635 | ||
| osteolysis | Q2035084 | ||
| P304 | page(s) | 2195-2202 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma | |
| P478 | volume | 100 |
| Q33941303 | A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites |
| Q39924762 | A role for leukemia inhibitory factor in melanoma-induced bone metastasis |
| Q42317482 | A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration |
| Q33393590 | An overview on bone manifestations in Gaucher disease |
| Q37638876 | Aseptic necrosis at multiple localisations in a lupus patient with lymphoma |
| Q42027903 | Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways |
| Q37828253 | Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities. |
| Q36737006 | Bone disease in multiple myeloma |
| Q34155848 | Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis |
| Q36177928 | CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease |
| Q37694678 | CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma |
| Q36925346 | Cellular mechanisms of multiple myeloma bone disease |
| Q57284923 | Chemokine analysis as a novel diagnostic modality in the early prediction of the outcome of non-union therapy: a matched pair analysis |
| Q41782043 | Chemokine expression is upregulated in chondrocytes in diabetic fracture healing |
| Q36596949 | Chemokines in multiple myeloma |
| Q36488894 | Clinical utilization of chemokines to combat cancer: the double-edged sword |
| Q28477867 | Computational modeling of interactions between multiple myeloma and the bone microenvironment |
| Q37234048 | Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis |
| Q46394413 | Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase |
| Q34121363 | Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts |
| Q36545216 | Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation |
| Q51734153 | Effective impairment of myeloma cells and their progenitors by hyperthermia. |
| Q36977712 | Extravasation and homing mechanisms in multiple myeloma |
| Q92859303 | Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples |
| Q48355113 | Immunological characterization of the early human fracture hematoma |
| Q54535110 | Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma. |
| Q34184457 | Inhibition of TACE activity enhances the susceptibility of myeloma cells to TRAIL. |
| Q33920086 | Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. |
| Q36141697 | MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. |
| Q40123747 | Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways |
| Q92965128 | Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies |
| Q34396114 | Mesenchymal stem cells markedly suppress inflammatory bone destruction in rats with adjuvant-induced arthritis |
| Q36453354 | Microarray-based understanding of normal and malignant plasma cells |
| Q49921429 | Multiple Myeloma and Bone: The Fatal Interaction |
| Q35901084 | Multiple myeloma/hypercalcemia |
| Q38598342 | Myeloma and Bone Disease |
| Q55209965 | Myeloma bone disease: Pathophysiology and management. |
| Q33564854 | Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration |
| Q37808649 | Osteoclastogenesis and arthritis |
| Q37235713 | Osteoimmunology: cytokines and the skeletal system |
| Q24655113 | Osteoimmunology: interactions of the bone and immune system |
| Q64117476 | PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ |
| Q38999733 | Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. |
| Q37591381 | Plasma cell leukemia producing monoclonal immunoglobulin E. |
| Q35557961 | Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis |
| Q47989365 | Primary adult T-cell leukemia/lymphoma of bone |
| Q37140665 | RANKL/RANK/OPG: key therapeutic target in bone oncology |
| Q40211681 | Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model |
| Q42316993 | Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors |
| Q89777495 | TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects |
| Q58790069 | Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy |
| Q53238656 | Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells. |
| Q37946702 | Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma |
| Q42546876 | Telomere length is positively associated with the expression of IL‑6 and MIP‑1α in bone marrow mesenchymal stem cells of multiple myeloma |
| Q28473419 | Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth |
| Q90227268 | The Cooperative Induction of CCL4 in Human Monocytic Cells by TNF-α and Palmitate Requires MyD88 and Involves MAPK/NF-κB Signaling Pathways |
| Q37541911 | The inflammatory chemokine CCL5 and cancer progression |
| Q35611123 | The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease |
| Q38724068 | The macrophage inflammatory proteins MIP1α (CCL3) and MIP2α (CXCL2) in implant-associated osteomyelitis: linking inflammation to bone degradation |
| Q37771082 | Tumor-host cell interactions in the bone disease of myeloma |
| Q39402922 | Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate |
| Q37270675 | VEGFR-2 reduces while combined VEGFR-2 and -3 signaling increases inflammation in apical periodontitis |
| Q46192240 | Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma |
| Q39908618 | Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production |
| Q37836495 | Why TNF-α inhibition is not sufficient to avoid juxta-articular erosions in chronic arthritis? |
| Q87885121 | [Interaction between myeloma cells and bone tissue] |
Search more.